


Global Chronic Obstructive Pulmonary Disease (COPD) Market to Reach USD 33.19 Billion by 2033 at a CAGR of 4.4% | FMI

COPD market grows with rising disease prevalence, innovation in therapies, and increasing global healthcare investments.

NEWARK, DE, UNITED STATES, April 28, 2025 /EINPresswire.com/ -- The global [chronic obstructive pulmonary disease](#) market is poised for substantial growth, with projections indicating a valuation of USD 21.58 billion in 2023. Driven by increasing alcohol consumption, tobacco use, and rapid urbanization, the demand for COPD-related therapies and products is expected to surge at a compound annual growth rate (CAGR) of 4.4% between 2023 and 2033. By the end of around USD 33.19 billion.



According to the Global Burden of Disease study conducted by the Institute of Health Metrics and Evaluation in 2016, there were approximately 251 million cases of COPD worldwide. The World Health Organization (WHO) further reported that around 200 million individuals globally were diagnosed with COPD in 2016. This high prevalence underscores the growing burden of the disease and the urgent need for effective management solutions.

COPD drugs market in the region. Asia Pacific is expected to hold the highest CAGR of 4.2% during the forecast period.”

*Sabyasachi Ghosh, Principal
Consultant. Future Market
Insights*

000000 000 0000000 0000000 0000000000000: 00000000 0
 0000000 0000000!

<https://www.futuremarketinsights.com/report->

Chronic Obstructive Pulmonary Disease (COPD) is a leading cause of death and disability worldwide, with a significant burden on the healthcare system.

The risk of developing COPD is exacerbated by rapid urbanization, particularly in emerging economies across the Asia Pacific region. Increased exposure to environmental pollutants, lung irritants, and industrial emissions is contributing significantly to the rising incidence of the disease. Furthermore, WHO emphasizes that exposure to tobacco smoke—both first-hand and second-hand—remains the most significant risk factor for COPD worldwide.

The increasing adoption of smoking habits among millennials, paired with a surge in alcohol consumption, has further intensified the demand for COPD treatments. At the same time, growing awareness about the availability and effectiveness of generic medications is expected to support market expansion, making treatments more accessible and affordable for a broader segment of the population.

The economic impact of COPD is substantial and growing, presenting significant growth opportunities for companies operating in the COPD market.

The economic impact of COPD is substantial and growing. According to the Centers for Disease Control and Prevention (CDC), the financial burden related to COPD in the United States was USD 32.1 billion in 2010, escalating to USD 49 billion by 2020. This continual rise in healthcare costs highlights the urgent need for innovative and cost-effective therapeutic solutions, thereby presenting significant growth opportunities for companies operating in the COPD market.

Key Market Segments

- **Geographic Segments:**

North America is expected to dominate the global COPD market with a 44% share in 2023, driven by a structured healthcare industry, strong reimbursement policies, ongoing R&D activities, rising smoking rates, and increasing air pollution.

- **Regional Segments:**

Asia Pacific is projected to hold the second-highest market share at 43% in 2023, fueled by a growing geriatric population, high disease incidence, and urbanization-induced air pollution, positioning the region for strong future growth.

- **Therapeutic Segments:**

The combination therapy segment leads the COPD market by drug class, accounting for 45% share and expected to grow at a CAGR of 4.3%, owing to higher treatment efficacy and increasing regulatory approvals.

- **Disease Segments:**

Chronic bronchitis is the leading type within the COPD market, holding a 43% share in 2022 and expected to expand at a CAGR of 4.2%, largely due to rising prevalence among smokers and

growing cases of airflow blockage.

• **Pharmaceutical Market Overview:**

Retail pharmacies captured 42% of the COPD market by distribution channel in 2022, with anticipated growth of 4.2% CAGR, supported by the expanding number of retail pharmacies and increased therapeutic dispensing.

For more information on the COPD market, visit our report: <https://www.futuremarketinsights.com/reports/chronic-obstructive-pulmonary-disease-copd-market>

Global COPD Market Overview

The global COPD market is characterized by intense competition, with key players focusing on product innovation, strategic partnerships, and expanding their geographic footprint. Some of the leading players in the market include:

- Almirall
- AstraZeneca
- Boehringer Ingelheim International GmbH
- CHIESI Farmaceutici S.p.A.
- F. Hoffmann-La Roche Ltd.
- GlaxoSmithKline plc.
- Kyowa Hakko Kirin
- Mylan N.V.
- Novartis AG
- Orion Corporation
- Sanofi
- Sunovion Pharmaceuticals, Inc. (a Sumitomo Dainippon Pharma Co., Ltd. company)
- Teva Pharmaceutical Industries Ltd.
- Theravance Biopharma
- Verona Pharmaceuticals

Verona Pharmaceuticals Market Overview

Verona Pharmaceuticals is a leading player in the COPD market, focusing on innovative therapies and expanding its global presence.

• In June 2022, Verona Pharma announced the completion of patient enrollment for its pivotal ENHANCE-1 trial, involving more than 800 subjects. The study aims to evaluate the efficacy of ensifentrine for the maintenance treatment of COPD. The company anticipates releasing top-line data for ENHANCE-1 by the end of 2022, with further insights from ENHANCE-2 expected in the third quarter of the year.

- In May 2022, Alembic Pharmaceuticals Ltd secured final approval from the U.S. Food & Drug Administration (USFDA) for its generic version of Arformoterol Tartrate inhalation solution, intended for the long-term treatment of bronchoconstriction in COPD patients. The approval covers a strength of 15 mcg (base)/2 mL unit-dose vial, adding a cost-effective therapeutic option to the U.S. market.

MARKET OPPORTUNITIES

THE COPD MARKET PRESENTS SEVERAL OPPORTUNITIES FOR PHARMACEUTICALS (TABLE 1) AND FOR DEVICE MANUFACTURERS:

- **NEW THERAPIES:**
 - o Combination Therapy
 - o Bronchodilators
 - o Corticosteroids
 - o Phosphodiesterase Type 4 Inhibitors
 - o Mucokinetics
 - o Others
- **NEW PATIENTS:**
 - o Chronic Bronchitis
 - o Emphysema
- **NEW DISTRIBUTION CHANNELS:**
 - o Hospital Pharmacies
 - o Retail Pharmacies
 - o Online Pharmacies
- **NEW REGIONS:**
 - o North America
 - o Europe
 - o Asia Pacific
 - o Latin America
 - o Middle East & Africa

MARKET OUTLOOK

The future of the COPD market looks promising as healthcare systems worldwide are increasingly focusing on early diagnosis, innovative treatment approaches, and public awareness campaigns to manage and mitigate the disease. With continued research, partnerships, and government support, the COPD market is expected to offer significant opportunities for both new entrants and established players over the next decade.

As COPD continues to pose a major global health challenge, the importance of innovation,

affordability, and accessibility in treatment solutions will be paramount. Stakeholders investing in next-generation therapies, respiratory support devices, and comprehensive disease management programs are poised to make a significant impact in improving patient outcomes and capturing a larger share of the growing market.

Ankush Nikam

Future Market Insights, Inc.

+91 90966 84197

[email us here](#)

Visit us on social media:

[LinkedIn](#)

[Facebook](#)

[YouTube](#)

[X](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/807280449>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.